 SAN DIEGO--BUSINESS WIRE--Odonate Therapeutics, Inc. NASDAQ: ODT, a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of Cohort 3 of CONTESSA TRIO, which will evaluate tesetaxel monotherapy in approximately 60 non-elderly patients with human epidermal growth factor receptor 2 HER2-negative metastatic breast cancer MBC. Cohort 3 of CONTESSA TRIO will complement Cohort 